ProQuad

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
22-07-2022
产品特点 产品特点 (SPC)
22-07-2022
公众评估报告 公众评估报告 (PAR)
08-10-2020

有效成分:

virus, live attenuated, measles, virus, live attenuated, mumps, virus, live attenuated, rubella, virus, live attenuated, varicella

可用日期:

Merck Sharp & Dohme B.V.

ATC代码:

J07BD54

INN(国际名称):

measles, mumps, rubella and varicella vaccine (live)

治疗组:

Vaccines

治疗领域:

Chickenpox; Rubella; Measles; Mumps; Immunization

疗效迹象:

ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age. ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles.,

產品總結:

Revision: 31

授权状态:

Authorised

授权日期:

2006-04-05

资料单张

                                38
B. PACKAGE LEAFLET
39
PACKAGE LE
AFLET: INFORMATION FOR THE USER
PROQUAD
POWDER AND SO
LVENT FOR SUSPENSION FOR INJECTION
Measles, mumps, rubella and varicella vac
cine (live)
R
EAD ALL OF THIS LEAFLE
T CAREFULLY BEFORE YOU OR YO
UR CHILD IS VACCINA
TED
BECAUSE IT CONTAINS
IMPORTANT INFORMATI
ON FOR YOU.
-
Keep this leaflet. You may ne
ed to read it again.
-
If you have any further questions, ask your doctor or your pharm
acist.
-
This
vaccine has been presc
ribed for you o
r your child
only. Do not pass i
t on to others.
-
If you get any of the sid
e effects, talk to your doctor or pharmacis
t. This inc
ludes any possible
side effects not listed in this leaflet.
See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pro
Quad is and wha
t it is used for
2.
What you need
to know before you receive ProQuad
3.
How
to use ProQuad
4.
Possible side effects
5.
How to store ProQuad
6.
Contents of the pack and other information
1.
WHAT PROQUAD I
S AND WHAT IT IS USED FOR
ProQuad
is a vaccine co
ntaining meas
les, mumps, rubella,
and chickenpox (varicella) viruses that
h
ave been weakened. When
a person is
given the vaccine, the immune system (the body’s natural
defences
) will make antibodies agains
t the measles,
mumps, rubella, and
varicella viruses. The
antibo
dies help protect against diseases caused by these viruses.
P
roQuad is given to help
protect you
r child against measles, mumps, rubella
, and chickenpox
(varicella)
. The vaccine may be adminis
tered to perso
ns from 12 months of
age.
ProQuad ma
y also be adm
inistered to infants from 9 months of age under special circum
stances (to
co
nform with national vaccination schedules, outbreak situatio
ns, or travel to a
region with high
prevalence of measle
s).
Although
ProQuad contains liv
e
viruses, they a
re too weak t
o cause measles, mumps, rubella, or
chickenpox (varicella) in
healthy people.
2.
WHAT YOU NEED TO KNOW BEFORE YOU
RECEIVE PROQUAD
DO
NOT USE PROQUAD

If the person to be vaccinated is aller
gic to any varicella
vaccine or mea
sles, mumps, or rubella
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY
OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ProQuad powder and solvent for suspension for injection
ProQuad powder and solvent for suspension for
injection in a pre-filled syringe
Measles, mump
s,
rubella and varicella vaccin
e (live).
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
After reconstitution, one dose (0.5
mL) contains:
Measles virus
1
Enders’ Edmonston strain (live, attenuated)
........ not less than 3.00 log
10
TCID
50
*
Mumps virus
1
Jeryl Lynn
™
(Le
vel B) strain (live, attenua
ted) ...
not less than 4.30 log
10
TCID
50
*
Rubella virus
2
Wistar RA 27/3 strain (live, attenuated)
...............
not less than 3.00 log
10
TCID
50
*
Varicella virus
3
Oka/Merck strain (live, attenuat
ed) ...................
not less than 3.99 log
10
PFU**
*50% tissue cultur
e infectious dose
**plaque-f
orming units
(
1
) Produced in chick embryo cells.
(
2
) Produced in human diploid lung (WI
-38) fibroblasts.
(
3
) Produced in human diploid (MRC
-5) cells.
The vaccine may contain
traces of recombinant human alb
umin (rHA).
This vacc
ine contains a trace amount
of neomycin. See section 4.3.
Excipient(s)
with known effect
The vaccine contains 16
milligrams
of sorbitol per dose.
See section 4.4.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder and solve
nt for suspension for injection
Before r
econstitution, the pow
der is a white to pale yellow
compact
crystalline cake and the solvent is
a clear colourless liquid.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
ProQuad is indicated for simultaneous
vaccination against measles, mumps, rub
ella and varicella in
individuals from 12
months of age.
ProQuad
can be administered to individuals from 9
months of
age under special circumstances (e.g.,
to conform with national vaccination sche
dules, outbreak
situations, or travel to a region with hig
h
prevalence of measle
s; see sections 4.2, 4.4, and
5.1).
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
ProQu
ad should be used in accordance to official r
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 22-07-2022
产品特点 产品特点 保加利亚文 22-07-2022
公众评估报告 公众评估报告 保加利亚文 08-10-2020
资料单张 资料单张 西班牙文 22-07-2022
产品特点 产品特点 西班牙文 22-07-2022
公众评估报告 公众评估报告 西班牙文 08-10-2020
资料单张 资料单张 捷克文 22-07-2022
产品特点 产品特点 捷克文 22-07-2022
公众评估报告 公众评估报告 捷克文 08-10-2020
资料单张 资料单张 丹麦文 22-07-2022
产品特点 产品特点 丹麦文 22-07-2022
公众评估报告 公众评估报告 丹麦文 08-10-2020
资料单张 资料单张 德文 22-07-2022
产品特点 产品特点 德文 22-07-2022
公众评估报告 公众评估报告 德文 08-10-2020
资料单张 资料单张 爱沙尼亚文 22-07-2022
产品特点 产品特点 爱沙尼亚文 22-07-2022
公众评估报告 公众评估报告 爱沙尼亚文 08-10-2020
资料单张 资料单张 希腊文 22-07-2022
产品特点 产品特点 希腊文 22-07-2022
公众评估报告 公众评估报告 希腊文 08-10-2020
资料单张 资料单张 法文 22-07-2022
产品特点 产品特点 法文 22-07-2022
公众评估报告 公众评估报告 法文 08-10-2020
资料单张 资料单张 意大利文 22-07-2022
产品特点 产品特点 意大利文 22-07-2022
公众评估报告 公众评估报告 意大利文 08-10-2020
资料单张 资料单张 拉脱维亚文 22-07-2022
产品特点 产品特点 拉脱维亚文 22-07-2022
公众评估报告 公众评估报告 拉脱维亚文 08-10-2020
资料单张 资料单张 立陶宛文 22-07-2022
产品特点 产品特点 立陶宛文 22-07-2022
公众评估报告 公众评估报告 立陶宛文 08-10-2020
资料单张 资料单张 匈牙利文 22-07-2022
产品特点 产品特点 匈牙利文 22-07-2022
公众评估报告 公众评估报告 匈牙利文 08-10-2020
资料单张 资料单张 马耳他文 22-07-2022
产品特点 产品特点 马耳他文 22-07-2022
公众评估报告 公众评估报告 马耳他文 08-10-2020
资料单张 资料单张 荷兰文 22-07-2022
产品特点 产品特点 荷兰文 22-07-2022
公众评估报告 公众评估报告 荷兰文 08-10-2020
资料单张 资料单张 波兰文 22-07-2022
产品特点 产品特点 波兰文 22-07-2022
公众评估报告 公众评估报告 波兰文 08-10-2020
资料单张 资料单张 葡萄牙文 22-07-2022
产品特点 产品特点 葡萄牙文 22-07-2022
公众评估报告 公众评估报告 葡萄牙文 08-10-2020
资料单张 资料单张 罗马尼亚文 22-07-2022
产品特点 产品特点 罗马尼亚文 22-07-2022
公众评估报告 公众评估报告 罗马尼亚文 08-10-2020
资料单张 资料单张 斯洛伐克文 22-07-2022
产品特点 产品特点 斯洛伐克文 22-07-2022
公众评估报告 公众评估报告 斯洛伐克文 08-10-2020
资料单张 资料单张 斯洛文尼亚文 22-07-2022
产品特点 产品特点 斯洛文尼亚文 22-07-2022
公众评估报告 公众评估报告 斯洛文尼亚文 08-10-2020
资料单张 资料单张 芬兰文 22-07-2022
产品特点 产品特点 芬兰文 22-07-2022
公众评估报告 公众评估报告 芬兰文 08-10-2020
资料单张 资料单张 瑞典文 22-07-2022
产品特点 产品特点 瑞典文 22-07-2022
公众评估报告 公众评估报告 瑞典文 08-10-2020
资料单张 资料单张 挪威文 22-07-2022
产品特点 产品特点 挪威文 22-07-2022
资料单张 资料单张 冰岛文 22-07-2022
产品特点 产品特点 冰岛文 22-07-2022
资料单张 资料单张 克罗地亚文 22-07-2022
产品特点 产品特点 克罗地亚文 22-07-2022
公众评估报告 公众评估报告 克罗地亚文 08-10-2020

查看文件历史